Review
Clinical Neurology
Alcira Suarez Moreno, Jean-Paul Nguyen, Astrid Calmelet, Estelle Le Saout, Philippe Damier, Laure de Decker, Catherine Malineau, Julien Nizard, Florence Canoui-Poitrine, Jean-Pascal Lefaucheur
Summary: This study evaluated the long-term effects of multi-site repetitive transcranial magnetic stimulation combined with cognitive training (NeuroAD procedure) on cognitive symptoms and apathy in patients with Alzheimer's disease (AD). The results showed that patients with a positive initial response to the 6-week treatment protocol exhibited long-term improvement in apathy and cognitive symptoms.
CLINICAL NEUROPHYSIOLOGY
(2022)
Article
Neurosciences
Haitham Salem, Robert Suchting, Mitzi M. Gonzales, Sudha Seshadri, Antonio L. Teixeira
Summary: This study aimed to detect conversion rates from mild cognitive impairment (MCI) to Alzheimer's disease (AD) and determine the effect of apathy on the progression to AD in patients with MCI. The study found that 17.3% of individuals had conversion from MCI to AD over a period of 8.21 years. Patients with apathy had a higher conversion rate and shorter time-to-conversion. Age and cognitive performance were found to moderate the relationship between apathy and time-to-conversion.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Geriatrics & Gerontology
Leonie C. P. Banning, Inez H. G. B. Ramakers, Paul B. Rosenberg, Constantine G. Lyketsos, Jeannie-Marie S. Leoutsakos
Summary: This study examined the trajectories of depression and apathy in (prodromal) Alzheimer's disease patients and found that they were associated with AD biomarkers. Lower A beta(42) and higher tau levels were related to increased probability of depression and apathy over time.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
(2021)
Article
Neurosciences
Stefano Giuseppe Grisanti, Federico Massa, Andrea Chincarini, Stefano Pretta, Roberto Rissotto, Carlo Serrati, Fiammetta Monacelli, Gianluca Serafini, Pietro Calcagno, Andrea Brugnolo, Matteo Pardini, Flavio Nobili, Nicola Girtler
Summary: Apathy and awareness of apathy can predict the progression and timing of dementia in patients with amnesic mild cognitive impairment (aMCI).
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Review
Clinical Neurology
Michael C. B. David, Martina Del Giovane, Kathy Y. Liu, Benjamin Gostick, James Benedict Rowe, Imafidon Oboh, Robert Howard, Paresh A. Malhotra
Summary: This study assessed the efficacy of drugs with noradrenergic action in improving cognitive and neuropsychiatric symptoms in Alzheimer's disease. The findings showed a small positive effect on global cognition and a large positive effect on apathy. This suggests that repurposing established noradrenergic drugs may offer effective treatment for certain symptoms in Alzheimer's disease.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Nutrition & Dietetics
Jonathan Bortz, Kevin C. Klatt, Taylor C. Wallace
Summary: This article discusses the factors influencing the risk of neurocognitive decline and Alzheimer's disease, with a focus on the interplay between cognitive aging, sex hormones, the cholinergic system, and essential nutrient choline. It highlights the neuroprotective effects of estrogen, particularly in interactions with the cholinergic system, and the potential impact on hormone replacement therapy and nutrient metabolism. The critical window hypothesis regarding estrogen's effects on the cholinergic system may have implications for future research in both preclinical and clinical settings.
ADVANCES IN NUTRITION
(2022)
Article
Neurosciences
Riccardo Manca, Sarah A. Jones, Annalena Venneri
Summary: Apathy is a common symptom in Alzheimer's disease and this study investigates the relationship between white matter damage and apathy. The study finds that apathetic patients have more severe neuropsychiatric symptoms and increased white matter damage. This damage may disrupt communication between different functional networks, resulting in motivational deficits and cognitive decline.
Article
Neurosciences
Miquel Aguilar-Barbera, Paquita Soler-Girabau, Ana Isabel Tabuenca-Martin, Laura Prieto-del Val
Summary: This study found that Fortasyn Connect, a nutritional supplement, can improve behavioral and psychological symptoms of dementia in patients with mild cognitive impairment and dementia, particularly symptoms of depression, anxiety, apathy, and irritability. The improvement is independent of patients' characteristics and treatment, but is more significant when the condition is severe and when treatment is initiated early.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Review
Pharmacology & Pharmacy
Xiaobo Wang, Jin-Bao Zhang, Kai-Jie He, Fen Wang, Chun-Feng Liu
Summary: Neurodegenerative diseases (NDD), such as Alzheimer's disease and Parkinson's disease, are characterized by neuron loss leading to motor and cognitive decline. Effective treatments for NDD are lacking, but zebrafish models show promise for drug discovery with their high homology to humans. High-throughput platforms in zebrafish research are expected to advance future NDD studies.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Neurosciences
Jean-Pierre Jacus, Virginie Voltzenlogel, Pascal Antoine, Christine-Vanessa Cuervo-Lombard
Summary: Previous studies have shown that apathy plays a major role in assessing the awareness of Alzheimer's patients. This research used the Apathy Evaluation Scales and other awareness scales to demonstrate that apathy is the only dimension that can differentiate between healthy individuals and Alzheimer's patients of varying severity. Additionally, the Mini-Mental State Examination score was found to be the best predictor and was associated with awareness of apathy.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Review
Pharmacology & Pharmacy
Shikha Kumari, Krishnaiah Maddeboina, Rinda Devi Bachu, Sai H. S. Boddu, Paul C. Trippier, Amit K. Tiwari
Summary: Alzheimer's disease is a progressive neurodegenerative disease with limited clinical options. Research is ongoing to find effective anti-AD compounds, and this review explores previous strategies, research findings, and success stories. Strategies for designing and developing small molecules for AD treatment are also proposed.
DRUG DISCOVERY TODAY
(2022)
Review
Neurosciences
Zhao-Di Xia, Ruo-Xin Ma, Jin-Feng Wen, Yu-Fei Zhai, Yu-Qi Wang, Feng-Yun Wang, Dan Liu, Xiao-Long Zhao, Bao Sun, Pu Jia, Xiao-Hui Zheng
Summary: This article reviews the complex pathophysiological mechanisms of Alzheimer's disease, including classical and recently proposed possible pathogenesis. It also outlines common animal models used in AD research and examines their prospects for the future. Additionally, the article summarizes clinical trials and drugs available for AD treatment.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Review
Clinical Neurology
Meysam Amidfar, Gholamreza Askari, Yong-Ku Kim
Summary: The discovery of biomarkers and the application of metabolomics can be useful for diagnosing and treating Alzheimer's disease and mild cognitive impairment, while investigating the relationship between nutritional behavior and Alzheimer's disease can provide preventive strategies against cognitive decline and dementia.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2024)
Review
Biochemistry & Molecular Biology
Dorit Trudler, Swagata Ghatak, Stuart A. Lipton
Summary: Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease, represent a significant social and economic burden due to increasing prevalence and lack of effective therapies. Lack of reliable models has hindered the development of treatments, but human-induced pluripotent stem cell technology offers a promising alternative to complement animal models for disease modeling and drug discovery.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Shan-Ju Yeh, Ming-Hsun Chung, Bor-Sen Chen
Summary: Alzheimer's disease (AD) is characterized by progressive cognitive decline and neurodegenerative disorder, with unclear molecular mechanisms. Research on candidate genetic and epigenetic networks (GEN) aims to identify potential biomarkers for drug targets in AD treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)